Skip to main content
Delfa

← All trials/NCT02340247

CompletedPhase 4

Effects of Bile Acids on GLP-1 Secretion After Roux-en-Y Gastric Bypass

Effects of Ursodeoxycholic Acid and Chenodeoxycholic Acid on GLP-1 Secretion After Roux-en-Y Gastric Bypass

Asset

GLP-1 / incretin class catch-all

Listed sites

1

Recruiting sites

-

Actual enrollment

11

Study population

Obesity / overweight

Eligibility highlights

-

Primary endpoint

•GLP-1 secretion (evaluated by iAUC)

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02340247
Org study IDSN-GALDE-14

Timeline

Milestones

Study first posted2015-01-16estimated
Last update posted2016-06-30estimated
Study start2014-11 (month precision)
Primary completion2015-04actual (month precision)

Assets

Investigational agents

GLP-1 / incretin class catch-all

Who this study enrolls

Obesity / overweight

Who can enroll

SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Uncomplicated RYGB performed minimum 3 months prior to the study.
•Fasting plasma glucose < 7.0mM, HbA1c < 48mmol/mol 3 months after RYGB.

Exclusion criteria

•Fasting plasma glucose > 7.0mM, HbA1c > 48mmol/mol 3 months after RYGB.
•Dysregulated hypothyroidism, use of antithyroid treatment.
•Late diabetic complications as retinopathy, renal insufficiency, neuropathy or previous pancreatitis.
•Complications to RYGB: Documented reactive hypoglycaemia, severe dumping (vomiting, diarrhea, severe abdominal pain after food intake).

Endpoints (10)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)
9
Glycemic / diabetes
1

Glycemic / diabetes

1 endpoint
Secondary/protocol endpoint

C-peptide secretion (evaluated by iAUC)

Time frame:Baseline, 0, 5, 10, 15, 20, 25, 30, 45, 60, 90, 120, 180

descriptive

Other (unclassified)

9 endpoints
Primary/protocol endpoint/low confidence

GLP-1 secretion (evaluated by iAUC)

Time frame:Baseline, 0, 5, 10, 15, 20, 25, 30, 45, 60, 90, 120, 180

descriptive

Secondary/protocol endpoint/low confidence

PYY secretion (evaluated by iAUC)

Time frame:Baseline, 0, 5, 10, 15, 20, 25, 30, 45, 60, 90, 120, 180

descriptive

Secondary/protocol endpoint/low confidence

Glucagon secretion (evaluated by iAUC)

Time frame:Baseline, 0, 5, 10, 15, 20, 25, 30, 45, 60, 90, 120, 180

descriptive

Secondary/protocol endpoint/low confidence

GIP secretion (evaluated by iAUC)

Time frame:Baseline, 0, 5, 10, 15, 20, 25, 30, 45, 60, 90, 120, 180

descriptive

Secondary/protocol endpoint/low confidence

CCK secretion (evaluated by iAUC)

Time frame:Baseline, 0, 5, 10, 15, 20, 25, 30, 45, 60, 90, 120, 180

descriptive

Secondary/protocol endpoint/low confidence

Gherlin secretion (evaluated by iAUC)

Time frame:Baseline, 0, 5, 10, 15, 20, 25, 30, 45, 60, 90, 120, 180

descriptive

Secondary/protocol endpoint/low confidence

Changes in bile acids/FGF-19

Time frame:Baseline, 0, 5, 10, 15, 20, 25, 30, 45, 60, 90, 120, 180

descriptive

Secondary/protocol endpoint/low confidence

TSH/T3/T4

Time frame:0, 60, 120, 180

descriptive

Secondary/protocol endpoint/low confidence

Appetite measurements (VAS-score)

Time frame:Baseline, 30, 60, 120, 180

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 6, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.